isis 183750
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01234038)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Eukaryotic translation initation factorANTISENSE INHIBITOR
EIF4E antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 183750
- isis eif4e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01675128 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01234025 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Ionis Pharmaceuticals, Inc. |
| NCT01234038 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Ionis Pharmaceuticals, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2012 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1